You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum

Article metrics

Article menu

Download PDFPDF

IGCS meeting abstracts
Plenary sessions
Plenary 1
IGCS19-0523
1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
Free

 

Online download statistics by month:

Online download statistics by month: September 2019 to April 2024

AbstractFullPdf
Sep 201930048
Oct 2019171066
Nov 201952040
Dec 201980021
Jan 2020101019
Feb 2020162043
Mar 2020120011
Apr 2020439033
May 2020264031
Jun 2020203024
Jul 2020120028
Aug 2020100018
Sep 2020150019
Oct 2020121019
Nov 202097014
Dec 20209003
Jan 2021132023
Feb 202183014
Mar 20216809
Apr 2021104018
May 202124012
Jun 20212010
Jul 20212012
Aug 2021109
Sep 20212012
Oct 202140015
Nov 202137019
Dec 20213908
Jan 20223806
Feb 20225409
Mar 20225108
Apr 20224607
May 202243012
Jun 20221503
Jul 20221805
Aug 20222208
Sep 20224808
Oct 20222606
Nov 202240010
Dec 20222100
Jan 20232503
Feb 20232101
Mar 20233405
Apr 20233504
May 20232302
Jun 20232406
Jul 20232408
Aug 20231602
Sep 20232302
Oct 20232301
Nov 20233803
Dec 20234502
Jan 20243200
Feb 20241801
Mar 202426030
Apr 20241404
Total36770754